MOTS-c (Human) identity testing starts with accurate mass on a high-resolution instrument. The result is matched to the calculated monoisotopic mass of C101H152N28O22S2. MS/MS sequence coverage backs it up, along with a single symmetrical RP-HPLC peak at the expected retention. Purity percentage is a separate measurement. It says nothing about which molecule is present.
- MOTS-c (Human) is the 16-residue peptide MRWQEMGYIFYPRKLR, molecular formula C101H152N28O22S2, monoisotopic mass about 2173.11 Da.
- A purity percentage describes homogeneity of the detected material and carries no information about which molecule the main peak represents.
- Intact accurate mass cannot distinguish leucine from isoleucine, cannot detect D-amino acids, and cannot detect a sequence permutation.
- Proline at position 12 produces a prominent y5 fragment ion, which makes MS/MS coverage of this sequence straightforward to interpret.
- Methionines at positions 1 and 6 plus tryptophan at position 3 make plus 16 and plus 32 dalton oxidation products expected at low level.
- There is no FDA or EMA approved medicine containing MOTS-c and no USP-NF monograph, so no compendial method or official reference standard exists.
What this guide covers
Purity tells you how clean a sample is, and identity tells you what the sample is. A glass of water can be perfectly clear and still be the wrong drink. Identity testing weighs the molecule and breaks it into pieces to check that it is MOTS-c and nothing else.
This guide explains how purity and identity differ, the numbers MOTS-c (Human) should produce, what accurate mass can and cannot settle, where sequence evidence comes from and what chromatography adds. It also covers the orthogonal tests worth asking for, why label mass differs from peptide mass, a step-by-step review of the identity evidence, what the certificate should show, the red flags, and the regulatory status. A bottom line closes it out.
- Retention time alone: weakest, transfers poorly between laboratories
- Single symmetrical peak with reported gradient: homogeneity, not identity
- Co-injection with qualified reference: retention becomes meaningful
- Accurate mass within a few ppm: confirms composition, not order
- Annotated MS/MS covering most amide bonds: confirms sequence
- Amino acid analysis and chiral assay: closes the isomer and epimer gaps
How do purity and identity differ?
A certificate that reports purity 99.1% by HPLC has answered exactly one question: of the material that absorbed at the detection wavelength and eluted from the column within the run time, what fraction sat under the main peak. It has said nothing about what that peak is.
The two failure modes look different on paper. Purity failures are heterogeneous: shoulders, satellite peaks, a baseline that will not settle. Identity failures are usually clean. A solid-phase synthesis that couples the wrong protected amino acid at one position, consistently, yields a single sharp peak of a single wrong compound. A deletion caused by an incomplete coupling followed by capping does the same. Either can pass a purity specification with room to spare, and a chromatogram alone will not object.
Identity therefore has to rest on measurements that respond to structure rather than to homogeneity: mass, fragmentation, amino acid composition, and where it matters, stereochemistry. Chromatography contributes to that case, in a supporting role, and only when the retention comparison is anchored to something outside the run.
What numbers should MOTS-c (Human) produce?
MOTS-c (Human) is a 16-residue linear peptide whose coding sequence sits within the mitochondrial 12S rRNA region (MT-RNR1). It was described in the peer-reviewed literature in 2015 as a mitochondrial-derived peptide. Research material is normally supplied as the trifluoroacetate salt of the free acid, with a free N-terminal amine, though the certificate has to say so rather than leaving it to be assumed.
| Attribute | Value |
|---|---|
| Sequence, one-letter | MRWQEMGYIFYPRKLR |
| Sequence, three-letter | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg |
| Residue count | 16 |
| Molecular formula | C101H152N28O22S2 |
| Monoisotopic mass | 2173.11 Da |
| Average mass | 2174.6 Da |
| [M+H]+ monoisotopic | 2174.12 |
| [M+2H]2+ | 1087.56 |
| [M+3H]3+ | 725.38 |
| [M+4H]4+ | 544.29 |
| Basic sites | Arg2, Arg13, Lys14, Arg16, N-terminus |
| Oxidation-prone residues | Met1, Met6, Trp3 |
Two practical consequences fall out of that table. Four basic sites plus the amine mean electrospray will populate the 2+ and 3+ channels generously, so a reported precursor at 1087.6 or 725.4 is the expected observation and a certificate quoting only a singly protonated species is worth a second look. And two sulfur atoms lift the M+2 isotope peak measurably above what a sulfur-free peptide of similar mass would show, which gives the isotope envelope itself a small amount of diagnostic value.
What can accurate mass settle, and what can it not?
A high-resolution measurement agreeing with 2173.11 Da to within a few parts per million is strong evidence about elemental composition. It is weaker evidence about structure than most certificates imply, because several plausible wrong products carry the same formula or differ by less than the instrument can resolve.
| Change | Mass shift (Da) | Seen by accurate mass? |
|---|---|---|
| Ile9 replaced by Leu, or Leu15 by Ile | 0.0000 | No, isomeric |
| D-amino acid at any position | 0.0000 | No |
| Any permutation of the same 16 residues | 0.0000 | No |
| Gln4 replaced by Lys | 0.0364 | Only at high resolving power with good calibration |
| Deamidation at Gln4 | +0.9840 | Yes |
| Single methionine sulfoxide | +15.9949 | Yes |
| Both methionines oxidized | +31.9898 | Yes |
| Gly7 deleted | −57.0215 | Yes |
| N-terminal or Lys14 acetylation | +42.0106 | Yes |
| Sodium adduct in place of a proton | +21.9819 | Yes |
The first three rows are the reason mass spectrometry cannot stand alone. A scrambled sequence and the correct sequence are indistinguishable at the level of intact mass, and a supplier who reports nothing but a matching molecular ion has demonstrated composition rather than order.
The oxidation rows matter for a different reason. With two methionines and a tryptophan, MOTS-c accumulates +16 and +32 species during handling and during the ionization process itself. Their presence at low level in a spectrum is ordinary. Their presence as the dominant species is a storage or handling finding, which is why oxidation-prone material belongs in cold, dark, dry conditions of the kind described in the guide on lyophilized peptide storage and stability.
Where does sequence evidence come from?
Fragmentation is the step that converts a composition match into a sequence claim. Collision-induced dissociation or HCD on the 2+ or 3+ precursor generates a b and y ion series, and the useful question is how much of the backbone those ions cover.
MOTS-c fragments cooperatively. Proline at position 12 produces preferential cleavage of the amide bond on its N-terminal side, giving a prominent y5 ion corresponding to Pro-Arg-Lys-Leu-Arg. The C-terminal arginine favors retention of charge on the y series generally, so the y ladder tends to be the better-populated of the two. The N-terminal Met-Arg pair usually yields a clean b2. Between them, a competent spectrum places most of the 15 amide bonds.
Fragmentation has two limits. Conventional low-energy fragmentation still cannot separate Ile9 from a leucine substitution; distinguishing them requires side-chain fragment ions of the w and d type, which need higher-energy or electron-transfer conditions and are rarely run on a routine release test. And no mass spectrometric method sees chirality. If the question on the table is whether a D-amino acid crept in during synthesis, mass spectrometry is the wrong instrument.
On the certificate, the useful artifact is an annotated product-ion spectrum with the matched ions labeled. A line reading sequence confirmed by MS/MS is only an assertion. It costs a laboratory nothing to attach the trace it already generated.
What is chromatography doing in the identity argument?
Reverse-phase HPLC on a C18 stationary phase with a water and acetonitrile gradient, both modified with 0.1% trifluoroacetic acid, is the standard release method. Detection at 214 or 220 nm reads the amide backbone. A second channel at 280 nm reads the aromatic residues, and MOTS-c has three of them: Trp3 plus Tyr8 and Tyr11.
That second channel earns its keep. The ratio of absorbance at 280 nm to absorbance at 214 nm is a crude structural fingerprint, because it depends on the aromatic content relative to backbone length. A material with the right mass but no tryptophan will not reproduce it. The check takes no extra injection.
Retention time, taken alone, proves almost nothing. It is a function of the column lot, the gradient, the temperature and the instrument dwell volume, and it transfers poorly between laboratories. What makes retention informative is comparison within the same analytical sequence against a qualified reference, and better still co-injection: spike the sample with reference material and look for a single peak that does not broaden. A spiked co-elution is real evidence. A retention time quoted on a certificate with no reference chromatogram beside it is a number without a frame.
Gradient steepness governs how much a purity figure is worth. A fast steep gradient compresses everything into a narrow window and will happily merge a truncated analog into the main peak. A shallow gradient across the region where the peptide elutes separates close relatives and produces a purity number that means something. This is why the method conditions belong on the certificate rather than in a supplier's internal file, and why our quality standard treats an unreported gradient as an incomplete result.
Which orthogonal tests are worth asking for?
Amino acid analysis hydrolyzes the peptide and quantifies the released residues chromatographically. It confirms composition independently of the mass spectrometer, it does resolve leucine from isoleucine, and it returns net peptide content as a by-product. Its weakness is that hydrolysis destroys tryptophan under standard acid conditions and partially converts glutamine to glutamate, so the expected recovery pattern for MOTS-c has known gaps that the report should acknowledge.
Chiral purity requires its own method: derivatization of the hydrolysate with a chiral reagent, or chiral gas chromatography, either of which will reveal a D-residue that every other test on the panel ignored. Few research-grade certificates include it. Asking is reasonable when the material is going into a structure-activity comparison where a single epimer would change the interpretation.
Karl Fischer titration gives water content. Ion chromatography quantifies the trifluoroacetate or acetate counterion. Neither is an identity test, and both are needed before anyone can say how much peptide a vial holds.
Why is label mass different from peptide mass?
A vial marked 10 mg holds 10 mg of lyophilized solid. That solid is peptide plus counterion plus residual water plus whatever salt the final purification left behind. For a TFA-salt peptide with four basic sites, net peptide content in the range of roughly 75 to 90 percent is unremarkable, and the certificate should state the figure with the method that produced it.
Take a vial labeled 10 mg with net peptide content reported at 82 percent:
10 mg × 0.82 = 8.2 mg peptide
An eighteen percent gap between label mass and peptide mass is large. It is enough to change what a comparison between two suppliers means, which is why the cost-per-mg tool is only honest when fed net peptide content rather than label mass.
Where net peptide content is absent from the certificate, the defensible position in a notebook is that the peptide mass is nominal and the true value unestablished. That is a smaller problem than recording a number you cannot support.
How to review MOTS-c identity evidence: step by step
The evidence for identity comes in links of different strength. Work through them from the weakest to the strongest, and note where each one stops being informative.
- Retention time alone is the weakest link, because it transfers poorly between laboratories.
- A single symmetrical peak with the gradient reported shows homogeneity. It does not show identity.
- Co-injection with qualified reference material is the point where retention becomes meaningful.
- Accurate mass within a few ppm confirms composition. It does not confirm order.
- An annotated MS/MS spectrum covering most amide bonds confirms the sequence.
- Amino acid analysis and a chiral assay close the isomer and epimer gaps.
What should a MOTS-c certificate show?
| Item | Acceptable | Weak or absent |
|---|---|---|
| Lot identifier | Unique, matches the vial label, with a test date after the manufacture date | Missing, or shared across products |
| Sequence | Printed in full, one- and three-letter, termini specified | Trade name only |
| Mass basis | Monoisotopic and average both given, with the measured one identified | One unlabeled number |
| Observed mass | Measured value, charge state, ppm error, instrument type | “Conforms to specification” |
| MS trace | Full spectrum with uncropped axes | Not attached |
| MS/MS | Annotated product-ion spectrum with matched ions | A sentence claiming confirmation |
| Purity method | Column and dimensions, mobile phases, gradient, wavelength, run time | “HPLC” |
| Chromatogram | Attached with visible integration | Not attached |
| Water content | Karl Fischer result | Absent |
| Counterion | Named and quantified | Absent |
| Net peptide content | Stated with method | Absent |
| Authorization | Named analyst or testing laboratory, dated | Unsigned template |
Red flags on a MOTS-c certificate
Any of these patterns should stop a review:
- The same retention time printed on certificates for chemically unrelated peptides, which indicates a template rather than a run.
- A molecular weight given to two decimal places without saying whether it is monoisotopic or average, when the two differ by about 1.5 Da here.
- Spectra with the intensity axis cropped so that adjacent species cannot be judged.
- Purity above 99.5% reported with no chromatogram, no gradient and no wavelength.
- An analysis date preceding the lot's stated manufacture date.
- Identity attributed to HPLC alone. Chromatography does not measure mass or sequence.
None of these prove the material is wrong. They establish that the document does not support the claim printed on it, which for record-keeping purposes amounts to the same thing.
What is the regulatory status of MOTS-c?
MOTS-c is a mitochondrial-derived peptide studied in academic settings since its description in 2015. As of the verification date below there is no medicine containing MOTS-c approved by the FDA or the EMA, and no monograph for it in the United States Pharmacopeia–National Formulary. Material in circulation is supplied as a research chemical, with a certificate of analysis covering identity and purity and nothing else.
That absence has a documentation consequence. Without a compendial monograph there is no official method, no official acceptance criterion and no reference standard with a pharmacopeial pedigree. Identity is established against calculated values and against whatever qualified in-house reference the testing laboratory maintains, and the certificate should say which.
Status verified August 26, 2026.
Bottom line
For MOTS-c (Human), a purity percentage says how clean the sample is and nothing about which molecule it is. Identity rests on accurate mass against 2173.11 Da monoisotopic, an annotated MS/MS spectrum, and orthogonal tests where isomers or epimers matter. Read net peptide content before trusting a label mass, and treat a certificate that cannot show its traces and method conditions as one that does not support its own claim.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Is a matching molecular weight enough to confirm MOTS-c identity?
Why does the certificate report two different molecular weights?
What does the 280 nm channel add to an HPLC purity run?
Should I expect oxidized species in the mass spectrum?
How much peptide is actually in a vial labeled 10 mg?
Can chromatographic retention time confirm identity on its own?
More documentation guides
Sources
- United States Pharmacopeia general chapter on mass spectrometry. Establishes expectations for accurate-mass measurement, calibration and reporting of observed ions; supports the requirement that charge state, measured value and mass error accompany an identity claim.
- United States Pharmacopeia general chapter on chromatography. Defines system suitability, peak integration and method reporting requirements; supports the position that a purity figure without column and gradient conditions is uninterpretable.
- United States Pharmacopeia general chapter on water determination. Karl Fischer methodology; supports the treatment of residual water as a separate measured contributor to lyophilizate gross mass.
- ICH Q6B, specifications for biotechnological and biological products. Framework distinguishing identity tests from purity and content tests, and the principle that identity requires methods responsive to structure; supports the orthogonal-testing argument.
